PMID- 19999149
OWN - NLM
STAT- MEDLINE
DCOM- 20100119
LR  - 20190917
IS  - 0009-918X (Print)
IS  - 0009-918X (Linking)
VI  - 49
IP  - 10
DP  - 2009 Oct
TI  - [Effects of acetylcholinesterase inhibitors on patients with MuSK antibody 
      positive myasthenia gravis].
PG  - 660-3
AB  - In order to clarify the clinical characteristics and effects of 
      acetylcholinesterase inhibitors of patients with generalized myasthenia gravis 
      with antibodies to muscle specific kinase (MuSK), we investigated seven patients 
      with MuSK antibodies and eleven patients without both antibodies of acetylcholine 
      receptor and MuSK. All patients with MuSK antibodies showed bulbar symptoms, 
      which frequency was significantly higher compared to those in patients without 
      double antibodies. The frequency of positive result of Tensilon test was 
      significantly lower in patients with MuSK antibodies than in those without double 
      antibodies. In response to intravenous edrophonium chloride, MuSK positive 
      patients showed adverse reactions in a small dosage of edrophonium chloride, less 
      than 5 mg, such as fasciculation on facial muscles and stuffy sensation of 
      throat. The adverse responses to a small dosage of intravenous edrophonium 
      chloride injection is useful information to distinguish patients with 
      seronegative generalized MG, whether they have MuSK antibodies or not. When 
      acetylcholinesterase inhibitors medication is tried to patients with MuSK 
      antibodies, if necessary, a small dosage of inhibitors should be used to avoid 
      cholinergic hypersensitivity.
FAU - Konishi, Tetsuro
AU  - Konishi T
AD  - Department of Neurology, Utano National Hospital.
FAU - Kousaka, Masayuki
AU  - Kousaka M
FAU - Yamakawa, Kentarou
AU  - Yamakawa K
FAU - Matsui, Masaru
AU  - Matsui M
FAU - Ohta, Kiyoe
AU  - Ohta K
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Rinsho Shinkeigaku
JT  - Rinsho shinkeigaku = Clinical neurology
JID - 0417466
RN  - 0 (Autoantibodies)
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0 (Receptors, Cholinergic)
RN  - EC 2.7.10.1 (MUSK protein, human)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Autoantibodies/*blood
MH  - Cholinesterase Inhibitors/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myasthenia Gravis/*drug therapy/*immunology
MH  - Receptor Protein-Tyrosine Kinases/*immunology
MH  - Receptors, Cholinergic/*immunology
EDAT- 2009/12/17 06:00
MHDA- 2010/01/20 06:00
CRDT- 2009/12/17 06:00
PHST- 2009/12/17 06:00 [entrez]
PHST- 2009/12/17 06:00 [pubmed]
PHST- 2010/01/20 06:00 [medline]
AID - 10.5692/clinicalneurol.49.660 [doi]
PST - ppublish
SO  - Rinsho Shinkeigaku. 2009 Oct;49(10):660-3. doi: 10.5692/clinicalneurol.49.660.